Histone deacetylase inhibitors (HDIs) are under investigation for the treatment of a number of human health problems. HDIs have proven therapeutic value in refractory cases of cutaneous T-cell lymphoma. Electrocardiographic ST segment morphological changes associated with HDIs were observed during development. Because ST segment morphology is typically linked to changes in ATP sensitive potassium (K\textsubscript{ATP}) channel activity, we tested the hypothesis that HDIs affect cardiac K\textsubscript{ATP} channel subunit expression. Two different HDIs, romidepsin and trichostatin A, caused ∼20-fold increase in SUR2 (Abcc9) subunit mRNA expression in HL-1 cardiomyocytes. The effect was specific for the SUR2 subunit as neither compound causes a marked change in SUR1 (Abcc8) expression. Moreover, the effect was cell specific as neither HDI markedly altered K\textsubscript{ATP} subunit expression in MIN6 pancreatic β-cells. We observe significant enrichment of the H3K9Ac histone mark specifically at the SUR2 promoter consistent with the conclusion that chromatin remodeling at this locus plays a role in increasing SUR2 gene expression. Unexpectedly, however, we also discovered that HDI-dependent depletion of cellular cholesterol is required for the observed effects on SUR2 expression. Taken together, the data in the present study demonstrate that K\textsubscript{ATP} subunit expression can be epigenetically regulated in cardiomyocytes, defines a role for cholesterol homeostasis in mediating epigenetic regulation and suggests a potential molecular basis for the cardiac effects of the HDIs.

Keywords: epigenetics, Abcc8, Abcc9, romidepsin, cholesterol, SREBP

Introduction

Histone deacetylase inhibitors (HDIs) have emerged as potential therapeutic agents for the treatment of cancer and heart disease (Ma et al., 2009; McKinsey, 2012). Histone deacetylases (HDACs) are known to be key co-factors of the machinery that regulates gene transcription. HDACs typically work in concert with DNA binding proteins to remove covalently...
attached acetyl groups from lysine residues contained within histone proteins, resulting in less accessible chromatin and reduced gene transcription (Kouzaries, 2007), however, this simple model of HDI action may belie the diverse effects of HDIs that can affect both normal and cancerous cell viability (Falkenberg and Johnstone, 2014).

To date, four HDIs—romidepsin, vorinostat, belinostat, and panobinostat—have been approved by the FDA for treating hematologic malignancies including refractory cutaneous T-cell lymphoma or multiple myeloma (Mann et al., 2007; Piekarz et al., 2011; Coiffier et al., 2012; Lee et al., 2015; Richardson et al., 2015). While HDIs have proven successful, cardiac safety has been a concern. Non-specific ST segment changes, long QT, atrial fibrillation, and torsades de pointes have all been reported in clinical trials (Sandor et al., 2002; Shah et al., 2006; Stadler et al., 2006; Steele et al., 2008; Lynch et al., 2012; Noonan et al., 2013). In a recent trial with romidepsin, the most common ECG finding was ST segment morphological changes with no evidence of associated myocardial ischemia (Noonan et al., 2013). ST segment elevation and depression are typically associated with the activation of ATP-sensitive (K_ATP) channels during ischemia (Kubota et al., 1993; Li et al., 2000), suggesting that HDIs may specifically affect K_ATP channel subunit expression in cardiac myocytes.

HDIs have also shown promise in the treatment of cardiovascular disease (McKinsey, 2012). Trichostatin A (TSA) interferes with phenylethylamine-induced hypertrophy of neonatal ventricular myocytes (Cao et al., 2011) and studies in animal models have shown that HDIs inhibit the development of cardiac hypertrophy due to angiotensin II infusion, aortic banding or pressure overload (Kee et al., 2006; Kong et al., 2006). HDIs have also been shown to inhibit the expression of hypertrophic genes, inflammatory markers, and fibrosis in the diseased heart (Liu et al., 2008; Cardinal et al., 2010; Cao et al., 2011). Interestingly, HDIs have also been shown to reduce infarct size and maintain contractile function following ischemia-reperfusion, similar to the effects of pharmacological or ischemic preconditioning (Zhao et al., 2007; Xie et al., 2014), which again is associated with activation of sarcolemmal K_ATP channels (Suzuki et al., 2002).

Based on these observations, we hypothesized that HDIs may specifically affect the expression of K_ATP channel subunits. A single K_ATP channel is a hetero-octomeric protein complex comprised of four pore-forming, inward rectifier (Kir6.1 or Kir6.2) and four sulfonylurea receptor (SUR1 or SUR2) subunits that are encoded by four separate genes (Inagaki et al., 1995a,b, 1996; Chutkow et al., 1999). Specific subunit combinations make up K_ATP channels in different tissues. For example, K_ATP channels in mouse atrial cardiomyocytes and pancreatic β-cells are composed of SUR1 and Kir6.2, while SUR2A and Kir6.2 form K_ATP in ventricular myocytes (Inagaki et al., 1995b, 1996; Flagg et al., 2008). There are relatively few studies to identify factors that regulate K_ATP channel subunit expression and many of these have been focused on pancreatic β-cell models rather than cardiomyocytes (Ashfield and Ashcroft, 1998; Hernandez-Sanchez et al., 1999; Kim et al., 2002). One study focused on myocardium demonstrated an important role for forkhead transcription factors in regulating K_ATP expression (Philip-Couderc et al., 2008), and we recently showed that DNA methylation can modulate SUR2 expression suggesting that epigenetic mechanisms may also regulate K_ATP subunit expression (Fatima et al., 2012). There have been no previous studies examining the effects of HDACs or HDIs on K_ATP subunit expression.

The results show that HDIs cause a specific increase in SUR2 expression in HL-1 cardiomyocytes but have no effect on MIN6 pancreatic β-cells indicating that HDIs have tissue specific mechanisms of action. Moreover, while HDAC-dependent histone acetylation likely contributes to the regulation of K_ATP expression, we made the unexpected discovery that TSA-dependent depletion of cholesterol was required for changes in SUR2 expression. Taken together the data demonstrate that HDIs specifically affect transcription of sarcolemmal K_ATP channel subunits and define a novel cholesterol-dependent mechanism that links HDIs with K_ATP subunit expression.

Materials and Methods

Cell Culture

Atrial myocyte derived HL-1 cell cultures were maintained in Claycomb medium (Sigma) (Claycomb et al., 1998). Cells were plated in tissue culture flasks coated overnight with gelatin (0.02% w/v) and fibronectin (0.5% v/v). MIN6 cells were maintained in DMEM containing 10% fetal bovine serum and 100 µg/mL penicillin/streptomycin. In all experiments to inhibit histone deacetylase (HDAC) activity, cells were incubated in standard culture medium supplemented with Trichostatin A (TSA) or Romidepsin at concentrations given in the text for 72 h. In some experiments, culture medium was also supplemented with cholesterol (250X cholesterol lipid concentrate, Gibco). Culture medium was changed daily.

Quantitative RT-PCR

Relative expression of K_ATP channel subunit mRNA was examined using quantitative RT-PCR, as described previously (Fatima et al., 2012). Total RNA was isolated using a silica-based column protocol (Qiagen, NENeasy) following the manufacturer’s protocols. Isolated RNA was then treated with DNAseI to digest residual genomic DNA and repurified using a silica-based column protocol (Qiagen, RNeasy) following the manufacturer’s protocols. Isolated RNA was then treated with DNAseI to digest residual genomic DNA and repurified using a silica-based column protocol. RNA concentration was determined spectrophotometrically (Nanodrop Technologies, Inc.). cDNA was synthesized from 1 µg RNA (Superscript III, Invitrogen). PCR was carried out using a CFX384 Real Time PCR Detection System (Bio-Rad, Inc.), using Taqman® probe and primer pairs (Applied Biosystems, Inc.) for monitoring reaction progress. Twenty nano gram of template cDNA was used in all reactions. Reactions with each primer/probe pair and template were performed in triplicate. Relative mRNA expression (compared to Hprt) is reported as 2^(-ΔΔCt) for untreated HL-1 and MIN6 cells. The fold change in expression in response to drug treatment is reported as 2^(-ΔΔCt), where ΔΔCt = ΔCt(drug) − ΔCt(nontreatment).

Protein Isolation and Western Analysis

Cells were washed with PBS and disrupted with RIPA lysis buffer (Santa Cruz) supplemented with protease inhibitors (Roche).
Protein concentration was determined by the BCA method (Pierce). For Western analysis, proteins (typically 50 μg) were separated by PAGE and transferred to PVDF membrane. Signal was visualized with the SuperSignal West Dura ECL substrate (Pierce).

**Chromatin Immunoprecipitation (ChIP)**

Chromatin immunoprecipitation (ChIP) assay was performed using the SimpleChIP enzymatic chromatin IP kit (Cell Signaling Technology) according to manufacturer’s protocol. Briefly, 1 × 10⁶ cells were incubated with 1% formaldehyde in 1X PBS for 10 min at room temperature followed by quenching with 0.125 M glycine for 5 min. After cell lysis, cross-linked chromatin was digested with micrococcal nuclease, followed by sonication to yield fragments of 200–1000 bp. Soluble chromatin fragments were incubated with antibodies against AChH3 (Abcam, ab-10812), control IgG (Cell Signaling Technology, 2729) and H3 (Cell Signaling Technology, 4620). Bound chromatin was precipitated using MagnaChip protein A+G magnetic beads (Millipore). Precipitated complexes were eluted, decrosslinked and purified. Purified DNA was amplified by qPCR with primer set corresponding to the promoter regions (~1 kb) for SUR1 and SUR2 (Qiagen). The data was analyzed according to comparative Ct method, normalized to IgG control and reported as fold change in binding relative to control.

**Genome-wide Expression Analysis**

MouseRef-8 v2.0 Expression BeadChips (Illumina Inc., San Diego, CA, USA) were used to measure relative levels of mRNA expression for 24,854 well-established annotated coding transcripts. Preparation of labeled cDNA, hybridization, imaging, and data collection were carried out at the Cleveland Clinic Genome Core Facility. Background subtracted, quantile normalized data were generated and analyzed using GenomeStudio (Illumina Inc., San Diego, CA, USA), GenePattern 2.0 (Broad Institute, Cambridge, MA, USA) and GATHER (Chang and Nevins, 2006) software packages. Four paired samples (treated and control) of each group were tested. Cells were treated with either TSA (30 mg/mL) or Romidepsin (5 nM). Differentially expressed transcripts were filtered using strict criteria for, accurate detection in at least three out of four samples, transcripts with 4-fold expression level differences and were regulated by both TSA and Romidepsin.

**Cholesterol Labeling with Filipin**

The protocols were adapted from the protocols of Leventhal et al. (2001). After treatment for 72 h with TSA or TSA combined with cholesterol, HL-1 and MIN6 cells were fixed in formalin for 10 min at room temperature. Fixed cells were labeled with filipin (0.05 mg/mL in PBS, Sigma) and PicoGreen (1:1000, Molecular Probes) for 1 h at room temperature to label non-esterified cholesterol and DNA, respectively. Images were obtained using a Leica AF6000 using the same exposure between samples within an experiment.

**Results**

**HDIs Increase SUR2 Subunit Expression in HL-1 Cardiomyocytes but not MIN6 Pancreatic β-cells**

The objective of the present study was to test the hypothesis that histone deacetylase inhibitors (HDIs) cause changes in K<sub>ATP</sub> channel subunit expression. For these studies, we made use of two cell lines that express K<sub>ATP</sub> channel subunits—HL-1 atrial cardiomyocytes and MIN6 pancreatic β-cells. Figure 1 shows the distribution of SUR1 and SUR2 in HL-1 cells. Expression of SUR1 is greater than SUR2 in both HL-1 and MIN6 cells, consistent with the distribution of subunits in primary tissue (Inagaki et al., 1995b, 1996; Flagg et al., 2008). In this study, we compared the responses of these two cell types to determine 1) if HDIs modulate K<sub>ATP</sub> expression and 2) if the effects are tissue specific.

Figure 2 shows the effects of HDAC inhibition on SUR1 and SUR2 mRNA expression in HL-1 cardiomyocytes. Treatment for 72 h with trichostatin A (TSA) induced a concentration-dependent increase in SUR2 mRNA expression with little or no change in SUR1. In contrast to the results with HL-1 cells, neither SUR1 nor SUR2 mRNA expression was markedly altered by HDAC inhibition in MIN6 pancreatic β-cells (Figure 2B). Taken together, these data demonstrate that HDIs do modulate K<sub>ATP</sub> subunit expression and that this occurs in a cell or tissue specific manner.

**Expression of SUR2 Correlates with Histone Acetylation at the Promoter**

To begin to elucidate the mechanism underlying the TSA-dependent increase in SUR2 expression, we confirmed that the HDAC inhibitors induced a global increase in histone acetylation in HL-1 cells. As expected, treatment with TSA significantly increased the amount of acetylated histone H3 and H4 without changes in the total histone protein (Figure 3A). Moreover, the increase in histone acetylation is concentration dependent and mirrors the concentration dependence of changes in SUR2 expression, suggesting that HDIs are influencing SUR2 expression through epigenetic histone modification. TSA also...
induces a similar increase in histone acetylation in MIN6 cells (Figure 3B). We examined the effects of TSA on gene specific histone acetylation using chromatin immunoprecipitation (ChIP). These results (Figure 3C) demonstrate a significant enrichment of the H3K9Ac histone mark at the SUR2, but not SUR1, promoter. Taken together, these data indicate that HDAC activity at the SUR2 promoter normally suppresses SUR2 transcription in HL-1 cardiomyocytes and that inhibition of this activity causes a specific increase in SUR2 expression.

**Genome-wide Expression Analysis Reveals Potential Role for Cholesterol Homeostasis**

To gain further mechanistic insight, we next performed a comprehensive genome-wide expression BeadArray profiling to determine the transcripts that are up- and down-regulated by HDIs in HL-1 cells (Figure 4). Three hundred fifty five genes were found to be increased or decreased more than 4-fold in the presence of TSA. Similarly, 415 genes were changed more than 4-fold by romidepsin with 171 genes common to the two data sets. Analysis of the data set using the GATHER software (Chang and Nevins, 2006) revealed marked changes in genes associated with muscle contraction (GO: 0006936), including Myh6, Ttn, Casq2, Tnni3, Acta1, Nppb, and Tnni2. qRT-PCR analysis confirmed at least 4-fold differential expression in five of the seven transcripts that we tested (Figure 4C). One of these transcripts (Tnni2) was expressed at very low levels and the other (Ttn) was only decreased 2.8-fold. We also annotated the 171 common gene dataset for enrichment of transcription factor binding sites (TRANSFAC v 8.2). Interestingly, this analysis demonstrated significant enrichment for sterol response element binding proteins (SREBPs) activity in response to HDIs. (60 of 171 transcripts, p < 0.0001). The enrichment of SREBP binding sites in the subset of transcripts affected by HDIs suggests that SREBP may play a role in mediating the effects of HDIs on K\textsubscript{ATP} channel subunit expression. This possibility was wholly unexpected, however, it should be pointed out that a previous study noted the presence of SREBP binding sites in the promoter regions of the SUR2 and Kir6.2 genes (Philip-Couderc et al., 2008), and therefore we followed up this lead.

**HDIs Specifically Deplete HL-1 Cells of Cholesterol**

A major physiological regulator of SREBP activity is cellular cholesterol. Reduced cholesterol levels in the endoplasmic reticulum trigger a sequence of events leading to cleavage of full length SREBP, allowing translocation of the transcriptionally active SREBP cleavage product to the nucleus (Jeon and Osborne, 2012). Interestingly, recent evidence suggests that HDIs can interfere with cholesterol homeostasis (Meaney, 2014). Therefore, we investigated the effects of TSA treatment on cellular cholesterol in HL-1 and MIN6 cells using filipin, a fluorescent antibiotic that has been used as a qualitative
FIGURE 4 | BeadArray profiling reveals a potential role for cholesterol and SREBP. (A) Venn diagram illustrating the number of genes specifically changed (≥4-fold increase or decrease). Analysis using GATHER software (Chang and Nevins, 2006) focused on the common gene set that was altered by both compounds. (B) Shown are the BeadArray signal intensities of seven transcripts that are included in the top gene ontology hit (GO:0006936: muscle contraction). (C) Expression changes were confirmed in 5 of 7 genes tested by qRT-PCR. (D) Annotation of common gene set for transcription factor binding sites (TRANSFAC, v8.2) revealed a putative role for SREBP in 60 out of 171 genes annotated.

measure of cellular cholesterol (Bittman and Fischkoff, 1972). TSA exposure markedly decreased filipin staining in HL-1 cells and cholesterol but did not affect filipin staining in MIN6 cells (Figure 5) suggesting that TSA-dependent cholesterol depletion might be required for TSA effects on gene expression.

**Cholesterol Suppresses the Effects of HDIs on K\textsubscript{ATP} Subunit Expression**

To determine whether TSA-dependent disruption of cholesterol homeostasis mediates the effects on K\textsubscript{ATP} expression, we assessed SUR2 expression in HL-1 cells incubated in culture medium supplemented with increasing concentrations of cholesterol and a constant concentration of TSA. Addition of cholesterol to the media completely restored cellular cholesterol as evidenced by the restoration of filipin staining (Figure 6A). Cholesterol also abolished the effects of TSA on gene expression in a concentration-dependent manner (Figure 6B). Importantly, TSA continued to inhibit HDAC activity as evidenced by the increase in acetylated H3 in the presence or absence of cholesterol. Taken together, this data indicates that cholesterol depletion is required for HDI-dependent effects on K\textsubscript{ATP} subunit expression in HL-1 cardiomyocytes.

**Discussion**

The data in the present study demonstrate two novel aspects regarding the transcriptional control of K\textsubscript{ATP} channel subunits. First, we show that inhibiting HDAC activity specifically increases SUR2 gene transcription in HL-1 cardiomyocytes. This result implies that under normal circumstances HDACs are recruited to the SUR2 gene locus in HL-1 cells contributing to the suppression of SUR2 expression in these cells under basal conditions. Second, we show that disruption of cellular cholesterol homeostasis is a critical mediator of HDI effects in HL-1 cells. This result implies that cholesterol homeostasis, in general, may be an important determinant of K\textsubscript{ATP} expression in the cardiovascular system.

**Specific Epigenetic Regulation of K\textsubscript{ATP} Channel Subunit Expression by HDACs**

Covalent histone modifications including acetylation, methylation, ubiquitylation, sumoylation, and phosphorylation are increasingly recognized as epigenetic regulators of when and where genes are actively expressed (Kouzarides, 2007). By promoting a more compact chromatin conformation, histone deacetylation is an important gene silencing factor. Here we show
that inhibiting HDAC activity increases SUR2 gene transcription in HL-1 cardiomyocytes. This is the first demonstration that HDIs can influence K\textsubscript{ATP} channel subunit expression providing evidence that K\textsubscript{ATP} channel subunit expression is normally determined in part by HDAC-dependent epigenetic regulation.

Specificity is a key feature of epigenetic regulation of K\textsubscript{ATP} channel expression. First, HDIs exhibit cell specific effects as evidenced by the observation that K\textsubscript{ATP} subunit expression is markedly affected in HL-1 cardiomyocytes but unaffected in MIN6 cells. HL-1 cells appear to be primed to express SUR2, but tonic suppression by HDACs normally maintains a low level of SUR2 expression. In contrast, the appropriate transcriptional activators of SUR2 expression appear to be absent in MIN6 cells and in this case suppression of SUR2 gene expression by HDACs would be redundant and is therefore not present. In addition to cell specificity, epigenetic regulation of K\textsubscript{ATP} channel expression is also subunit specific. HDIs specifically increase histone acetylation at the SUR2 gene but have no effect at the SUR1 locus. This demonstrates that HDACs are recruited specifically to the SUR2 locus in order to establish the pattern of K\textsubscript{ATP} subunit expression observed in HL-1 cells.

**HDI Therapy, Epigenetics, and Arrhythmia**

Disruption of the appropriate K\textsubscript{ATP} channel composition or function has been shown to cause arrhythmias or abnormal ECG responses to ischemia. Using transgenic models that overexpress K\textsubscript{ATP} subunits, we have shown that disrupting normal K\textsubscript{ATP} composition by overexpressing SUR1 is arrhythmogenic (Flagg et al., 2007), illustrating the importance of establishing the appropriate channel composition in the mouse heart (Flagg et al., 2008; Glukhov et al., 2010). Genetic or pharmacologic inhibition of K\textsubscript{ATP}, for example, completely abolishes the ST segment elevation associated with ischemia (Kubota et al., 1993; Li et al., 2000) and K\textsubscript{ATP} channel openers such as pinacidil have been shown to induce ST segment elevation independent of ischemia (Yan and Antzelevitch, 1999). K\textsubscript{ATP} is a particularly potent means of modulating cardiac action potential duration. Activation of just 1% of the total K\textsubscript{ATP} channels available has been shown to shorten the APD by 50% (Nichols et al., 1991; Weiss et al., 1992; Knopp et al., 1999). Moreover, in ischemia models it has been shown that shortening of APD by only about 20% is correlated with marked ST elevation of about 5–10 mV (Kingaby et al., 1986). Based on these observations, it is possible that even very small changes in K\textsubscript{ATP} could be manifest as changes in the ECG.

The onset of cardiac arrhythmias has been observed in several clinical and pre-clinical studies of HDI therapy (Berry et al., 2008). Ventricular tachycardia, torsades de pointes, and atrial fibrillation have been reported as rare cardiovascular events in early phase trials of HDIs (Sandor et al., 2002; Kelly et al., 2005; Pickarz et al., 2006; Lynch et al., 2012). The major cardiac effect associated with romidepsin therapy is asymptomatic, non-specific, ischemia-independent ST segment elevation or depression (Sandor et al., 2002; Pickarz et al., 2006; Noonan et al., 2013). Because ST segment elevation is typically associated with activation of K\textsubscript{ATP} channels (Kubota et al., 1993; Li et al., 2000), the cardio-specific effects of romidepsin and TSA on K\textsubscript{ATP} channel subunit expression provide a potential molecular basis for the cardiac effects associated with HDIs. Similarly, re-entrant arrhythmias can be promoted by activation of K\textsubscript{ATP} (Billman, 2008). Other mechanisms such as decreased connexin 43 expression (Xu et al., 2013) or non-specific HERG blockade have been suggested to account for the cardiac effects of HDI therapy. Here we suggest that epigenetic alterations in cardiac K\textsubscript{ATP} channel expression may also contribute to the electrophysiological events observed during HDI-therapy.

**HDIs, Cholesterol, and K\textsubscript{ATP} Expression**

The second major finding in this study is the discovery of a key role for cholesterol depletion in mediating the effect of HDIs on SUR2 expression. The key clue that focused attention on cholesterol was the association of SREBP with the gene changes induced by the HDIs (Figure 4). SREBPs are transcription factors that are typically associated with cellular lipid homeostasis (Jeon and Osborne, 2012). Previous studies have linked HDIs with a reduction of cholesterol. For example, Niemann-Pick C disease causes intracellular cholesterol accumulation as a result of mutations in the NPC1 or NPC2 gene product that are critical for cholesterol trafficking (Ory, 2004 and HDIs have been shown to largely correct the cholesterol accumulation phenotype both in fibroblasts cultured from human NPC patients (Pipalia et al., 2011) and neural stem cells from NPC mice (Kim et al., 2007). Similarly, others have shown that TSA causes a significant reduction in cellular cholesterol by increasing expression of genes that traffic and export cholesterol.
as well as inhibiting expression of genes in the mevalonate pathway of cholesterol synthesis (Nunes et al., 2013). The specific molecular mechanisms driving cholesterol reduction in HL-1 cells in the present study remain to be determined as does the cell-specific basis for the HDI effects on cholesterol homeostasis. Nevertheless, it is clear that HDIs significantly disrupt cellular lipid homeostasis in HL-1 cardiomyocytes, but not MIN6 pancreatic β-cells.

The data indicate that maintaining cellular cholesterol prevents the effect of HDIs on K<sub>ATP</sub> subunit expression. This finding suggests the very intriguing conclusion that there is a link between cellular cholesterol homeostasis and K<sub>ATP</sub> expression. There have been no previous studies that directly link cholesterol homeostasis with K<sub>ATP</sub> channel expression. In silico analysis previously identified SREBP binding sites in the SUR2 and Kir6.2 promoters (Philip-Couderc et al., 2008), but the functional relevance of those putative binding sites has not specifically been explored. Interestingly, there have been studies that indirectly link cholesterol homeostasis with K<sub>ATP</sub> expression. Hypercholesterolemia, which is expected to inhibit SREBP, has been associated with impaired ischemic preconditioning (Csonka et al., 2014) which requires functional sarcolemmal K<sub>ATP</sub> channels (Suzuki et al., 2002). It should also be noted that there is a precedent for lipid homeostasis and SREBP in regulating the expression of an inward rectifying potassium channel. Park and colleagues demonstrated that lipid lowering leads to an increase in GIRK1 expression through activation of SREBP-1 (Park et al., 2008). The present results suggest that cholesterol homeostasis and lipid metabolism in general may have analogous effects on K<sub>ATP</sub> subunit expression with consequent arrhythmias.

**Conclusion**

In summary, the results presented in this study demonstrate that HDIs such as TSA and romidepsin cause marked changes in the expression of K<sub>ATP</sub> channel subunits. This defines a role for HDACs in determining which K<sub>ATP</sub> channel subunits are expressed in cardiomyocytes but not pancreatic β-cells. Moreover, the data demonstrate a key role for cholesterol homeostasis in regulating this process. Taken together, these novel observations could lead to new strategies to modulate sarcolemmal K<sub>ATP</sub> channel structure and function in the heart where it protects against stress and ischemia (Flagg et al., 2010). Moreover, our observations may explain the ST segment morphological changes that are associated with HDI therapy in cancer patients.

**Acknowledgments**

The authors thank the Biomedical Instrumentation Center at USUHS for providing advanced microscope technology and support for imaging experiments. This work was supported by awards from the American Heart Association Scientist Development Grant (11SDG7210070 to TF) and the Department of Defense (R0702O to TF).

**Disclaimer**

The views expressed are those of the authors and do not reflect the official policy or position of the Uniformed Services University of the Health Sciences, the Department of the Defense, or the United States government.

**References**

Ashfield, R., and Ashcroft, S. J. (1998). Cloning of the promoters for the beta-cell ATP-sensitive K<sub>channel</sub> subunits Kir6.2 and SUR1. Diabetes 47, 1274–1280. doi: 10.2373/diabetes.47.8.1274

Berry, J. M., Cao, D. J., Rothermel, B. A., and Hill, J. A. (2008). Histone deacetylase inhibition in the treatment of heart disease. Expert Opin. Drug Saf. 7, 53–67. doi: 10.1517/14740338.7.1.53

Billman, G. E. (2008). The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arhythmic therapy. Pharmacol. Ther. 120, 54–70. doi: 10.1016/j.pharmthera.2008.07.004

Bittman, R., and Fischkoff, S. A. (1972). Fluorescence studies of the binding of the polyene antibiotics filipin 3, amphotericin B, nystatin, and lagosin to cholesterol. Proc. Natl. Acad. Sci. U.S.A. 69, 3795–3799. doi: 10.1073/pnas.69.12.3795

Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., et al. (2011). Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc. Natl. Acad. Sci. U.S.A. 108, 4123–4128. doi: 10.1073/pnas.1015081108

Cardinale, J. P., Siramula, S., Pariaut, R., Guggilam, A., Mariappan, N., Elks, C. M., et al. (2010). HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 56, 437–444. doi: 10.1161/HYPERTENSIONAHA.110.154567

Chang, J. T., and Nevin, J. R. (2006). GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22, 2926–2933. doi: 10.1093/bioinformatics/btl483

Chutkov, W. A., Makielki, J. C., Nelson, D. J., Burant, C. F., and Fan, Z. (1999). Alternative splicing of sur2 Exon 17 regulates nucleotide sensitivity of the ATP-sensitive potassium channel. J. Biol. Chem. 274, 13656–13665. doi: 10.1074/jbc.274.19.13656

Claycomb, W. C., Lansen, N. A. Jr., Stallworth, B. S., Egeland, D. B., Delcarpio, J. B., Bahinski, A., et al. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl. Acad. Sci. U.S.A. 95, 2979–2984. doi: 10.1073/pnas.95.6.2979

Coiffier, B., Pro, B., Prince, H. M., Foss, F., Sokol, L., Greenwood, M., et al. (2012). Results From a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30, 631–636. doi: 10.1200/JCO.2011.37.4223

Csonka, C., Kupai, K., Bencsik, P., Górecki, A., Pálóczi, J., Zveri, A., et al. (2014). Cholesterol-enriched diet inhibits cardioprotection by ATP-sensitive K<sub>channel</sub> activators cromakalim and diazoxide. Am. J. Physiol. Heart Circ. Physiol. 306, H405–H413. doi: 10.1152/ajpheart.00257.2013

Falkenberg, K. J., and Johnstone, R. W. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673–691. doi: 10.1038/nrd4360

Fatima, N., Schooley, J. F. Jr., Claycomb, W. C., and Flagg, T. P. (2012). Promoter DNA methylation regulates murine SUR1 (Abcc8) and SUR2 (Abcc9) expression in HL-1 cardiomyocytes. PLoS ONE 7:e41533. doi: 10.1371/journal.pone.0041533

Flagg, T. P., Enkvetchakul, D., Koster, J. C., and Nichols, C. G. (2010). Muscle K<sub>ATP</sub> channels: recent insights to energy sensing and myo-protection. Physiol. Rev. 90, 799–829. doi: 10.1152/physrev.00027.2009

Flagg, T. P., Kurata, H. T., Masia, R., Caputa, G., Magnuson, M. A., Defer, D. J., et al. (2008). Differential structural of atrial and ventricular K<sub>ATP</sub> channels require SUR1. Circ. Res. 103, 1458–1465. doi: 10.1161/CIRCRESAHA.108.178186
Flagg, T. P., Patton, B., Masia, R., Mansfield, C., Lopatin, A. N., Yamada, K. A., et al. (2007). Arrhythmia susceptibility and premature death in transgenic mouse overexpressing both SUR1 and Kir2.2[Delta][N30,K185Q] in the heart. Am. J. Physiol. Heart Circ. Physiol. 293, H836–H845. doi: 10.1152/ajpheart.00011.2007
Glukhov, A. V., Flagg, T. P., Fedorov, V. V., Elmov, I. R., and Nichols, C. G. (2010). Differential KATP channel pharmacology in intact mouse heart. J. Mol. Cell Cardiol. 48, 152–160. doi: 10.1016/j.yjmcc.2009.08.026
Hernández-Sánchez, C., Ito, Y., Ferrer, J., Reitman, M., and Le Roth, D. (1999). Characterization of the Mouse Sulfonylurea Receptor 1aPromotor and its regulation. J. Biol. Chem. 274, 18261–18270. doi: 10.1074/jbc.274.26.18261
Inagaki, N., Gonoi, T., Clement, J. P., Namba, N., Inazawa, J., Gonzalez, G., et al. (1995b). Reconstitution of I-Katp—an inward rectifier subunit plus the sulfonylurea receptor. Science 270, 1166–1170. doi: 10.1126/science.270.5239.1166
Inagaki, N., Gonoi, T., Clement, J. P., Wang, C. Z., Aguilar-Bryan, L., Bryan, J., et al. (1996). A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 16, 1011–1017. doi: 10.1016/S0896-6278(00)80124-5
Inagaki, N., Inazawa, J., and Seino, S. (1995a). cDNA sequence, gene structure, and chromosomal localization of the human ATP-sensitive potassium channel, uKATP-1 gene (KCNN8). Genomics 30, 102–104. doi: 10.1006/geno.1995.0018
Jeon, T. I., and Osborne, T. F. (2012). SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol. Metab. 23, 65–73. doi: 10.1016/j.tem.2011.10.004
Kee, H. J., Sohn, I. S., Nam, K. I., Park, J. E., Qian, Y. R., Yin, Z., et al. (2006). Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with peripheral T-cell lymphoma. Clin. Cancer Res. 12, 3104–3109. doi: 10.1158/1078-0432.CCR-13-0189
Nunes, M. J., Moutinho, M., Gama, M. J., Rodrigues, C. M., and Rodrigues, E. (2013). Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux. PLoS ONE 8:e55394. doi: 10.1371/journal.pone.0055394
Ory, D. S. (2004). The niemann-pick disease genes: regulators of cellular cholesterol homeostasis. Trends Cardiovasc. Med. 14, 66–72. doi: 10.1016/j.tcm.2003.12.003
Park, H. J., Georgescu, S. P., Du, C., Madias, C., Aronovitz, M. J., Welz, C. G., et al. (2008). Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J. Clin. Invest. 118, 259–271. doi: 10.1172/JCI31201
Philip-Couderc, P., Tavares, N. L., Roatti, A., Lerch, R., Montessuit, C., and Baetschi, A. J. (2008). Forkhead transcription factors coordinate expression of myoccardial kapt channel subunits and energy metabolism. Circ. Res. 102, e20–e35. doi: 10.1161/CIRCRESAHA.107.166744
Piekarski, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., et al. (2006). Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin. Cancer Res. 12, 3762–3773. doi: 10.1158/1078-0432.CCR-05-2095
Piekarski, R. L., Frye, R. R., Prince, K. H., Scharnberg, W. M., Hain, J., Allen, S. L., et al. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117, 5827–5834. doi: 10.1182/blood-2010-10-312603
Pipalia, N. H., Cosner, C. C., Huang, A., Chartterjee, A., Bourbon, P., Farley, N., et al. (2011). Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick C1 mutant human fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 108, 5620–5625. doi: 10.1073/pnas.101490108
Richardson, P. G., Laubach, J. P., Lonial, S., Moreau, P., Yoon, S.-S., Hungria, V. T., et al. (2015). Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma. Expert Rev. Anticancer Ther. 15. 737–748. doi: 10.1586/14737442.2015.1047770
Sandor, V., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, V. T., et al. (2002). Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718–728.
Shah, M. H., Binkley, P., Chan, K., Xiao, J., Arboagast, D., Collamore, M., et al. (2006). Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 12, 3997–4003. doi: 10.1158/1078-0432.CCR-05-2689
Stadler, W. M., Margolin, K., Ferber, S., McCulloch, W., and Thompson, J. A. (2006). A Phase II study of depsipeptide in refractory metastatic renal cell cancer. Genitourin. Cancer 5, 57–60. doi: 10.1086/361812
Teel, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., et al. (2008). A Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14, 804–810. doi: 10.1158/1078-0432.CCR-07-1786
Suzuki, M., Sasaki, N., Miki, T., Sakamoto, N., Ohmoto-Sekine, Y., Tamagawa, M., et al. (2002). Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. *J. Clin. Invest.* 109, 509–516. doi: 10.1172/JCI0214270

Weiss, J. N., Venkatesh, N., and Lamp, S. T. (1992). ATP-sensitive K+ channels and cellular K+ loss in hypoxic and ischaemic mammalian ventricle. *J. Physiol.* 447, 649–673. doi: 10.1113/jphysiol.1992.sp019022

Xie, M., Kong, Y., Tan, W., May, H., Battiprolu, P. K., Pedrozo, Z., et al. (2014). Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. *Circulation* 129, 1139–1151. doi: 10.1161/CIRCULATIONAHA.113.002416

Xu, Q., Lin, X., Andrews, L., Patel, D., Lampe, P. D., and Veenstra, R. D. (2013). Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication. *Front. Pharmacol.* 4:44. doi: 10.3389/fphar.2013.00044

Yan, G. X., and Antzelevitch, C. (1999). Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. *Circulation* 100, 1660–1666. doi: 10.1161/01.CIR.100.15.1660

Zhao, T. C., Cheng, G., Zhang, L. X., Tseng, Y. T., and Padbury, J. F. (2007). Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. *Cardiovasc. Res.* 76, 473–481. doi: 10.1016/j.cardiores.2007.08.010

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.